PubRank

Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2.

PubWeight™: 0.91‹?›

🔗 View Article (PMID 24215846)

Published in Eur J Cancer on November 08, 2013

Authors

Anne V Soerensen1, Frede Donskov2, Gregers G Hermann3, Niels V Jensen4, Astrid Petersen5, Henrik Spliid6, Rickard Sandin7, Kirsten Fode2, Poul F Geertsen8

Author Affiliations

1: Department of Oncology, University Hospital of Copenhagen Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark. Electronic address: Anne.Vest.Soerensen@regionh.dk.
2: Department of Oncology, Aarhus University Hospital, Noerrebrogade 44, 8000 Aarhus, Denmark.
3: Department of Urology, University Hospital of Copenhagen Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark.
4: Department of Oncology, Odense University Hospital, Sdr. Boulvard 29, 5000 Odense, Denmark.
5: Department of Pathology, Aalborg University Hospital, Ladegaardsgade 3, Postbox 561, 9100 Aalborg, Denmark.
6: Technical University of Denmark, Bygning 303B, 2800 Kongens Lyngby, Denmark.
7: Pfizer Oncology, Vetenskapsvägen 10, 19190 Sollentuna, Sweden.
8: Department of Oncology, University Hospital of Copenhagen Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark.

Articles citing this ↘

Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer. Cancer J (2014) 0.88

A five-factor biomarker profile obtained week 4-12 of treatment for improved prognostication in metastatic renal cell carcinoma: Results from DARENCA study 2. Acta Oncol (2015) 0.80

Survival among patients with advanced renal cell carcinoma in the pretargeted versus targeted therapy eras. Cancer Med (2015) 0.79

Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study. Onco Targets Ther (2017) 0.78

First-line Mammalian target of rapamycin inhibition in metastatic renal cell carcinoma: an analysis of practice patterns from the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer (2014) 0.76

Pazopanib as a second-line treatment for non-cytokine-treated metastatic renal cell carcinoma: a meta-analysis of the effect of treatment. BMC Urol (2016) 0.75

Genetic and Chromosomal Aberrations and Their Clinical Significance in Renal Neoplasms. Biomed Res Int (2015) 0.75

Maslinic Acid Inhibits Proliferation of Renal Cell Carcinoma Cell Lines and Suppresses Angiogenesis of Endothelial Cells. J Kidney Cancer VHL (2017) 0.75